Browsing by Author "Oğuzülgen İ.K."
Now showing 1 - 4 of 4
Results Per Page
Sort Options
Item Country-based report: The safety of omalizumab treatment in pregnant patients with asthma(Turkiye Klinikleri, 2021) Gemicioğlu B.; Yalçin A.D.; Havlucu Y.; Karakaya G.; Özdemir L.; Keren M.; Bavbek S.; Ediger D.; Oğuzülgen İ.K.; Özşeker Z.F.; Yorgancioğlu A.Background/aim: We aimed to report outcomes of pregnant patients with asthma under omalizumab treatment and their infants in our country. Materials and methods: Patients with asthma who received omalizumab for at least 6 months and at least one dose during their pregnancy were retrospectively evaluated using a questionnaire regarding their disease and therapy and the health of their infants. Results: Twenty pregnant patients and their 23 infant’s data were analyzed. The mean delivery age was 31.8 ± 7.4 years. They received omalizumab for 28.9 ± 21.8 months. Eight (36.4%) patients showed exacerbation of the disease during pregnancy. Forced expiratory volume in 1 s (FEV1) and asthma control test (ACT) scores at the starting time of omalizumab administration, first month of the pregnancy, and after delivery were 71 ± 18%, 83.4 ± 10.5%, and 80.5 ± 13% (FEV1), and 11.9 ± 4.9, 20.2 ± 2.6, and 20.4 ± 2.2 (ACT), respectively. One patient gave birth to twin infants, two patients to two infants each in different years, and 17 to one infant each. Three (13%) infants had low birth weight and five (21.7%) were born prematurely. No congenital anomalies were detected. Seven (30.4%) infants presented atopic diseases during their life. Conclusion: Omalizumab treatment during pregnancy seems to be safe for both patients and their infants. © TÜBİTAK.Item Stepwise Approach in Asthma Revisited 2023: Expert Panel Opinion of Turkish Guideline of Asthma Diagnosis and Management Group(AVES, 2023) Çelik G.E.; Aydın Ö.; Damadoğlu E.; Baççıoğlu A.; Özdemir S.K.; Bavbek S.; Ediger D.; Erkekol F.Ö.; Gemicioğlu B.; Işık S.R.; Kalpaklıoğlu A.F.; Kalyoncu A.F.; Karakaya G.; Keren M.; Mungan D.; Oğuzülgen İ.K.; Yıldız F.; Yılmaz İ.; Yorgancıoğlu A.Introduction of inhaled corticosteroids (ICS) has been the cornerstone of the long-term management of asthma. ICSs either alone or in combination with long-acting beta-2 agonists have been shown to be associated with favorable asthma outcomes. However, asthma con-trol is still reported to be below expectations all around the world. Research in the last decades focusing on the use of ICS/formoterol both as maintenance and as needed (maintenance and reliever therapy approach) showed improved asthma outcomes. As a result of recent developments, Turkish Asthma Guidelines group aimed to revise asthma treatment recommendations. In general, we recommend physicians to consider the risk factors for poor asthma outcomes, patients’ compliance and expectations and then to determine “a personalized treatment plan.” Importantly, the use of short-acting beta-2 agonists alone as a symptom reliever in asthma patients not using regular ICS is no longer recommended. In stepwise treatment approach, we primarily recommend to use ICS-based controllers and initiate ICS as soon as possible. We define 2 different treatment tracks in stepwise approaches as maintenance and reliever therapy or fixed-dose therapy and equally recommend each track depending on the patient’s risks as well as decision of physicians in a personalized manner. For both tracks, a strong recommendation was made in favor of using add-on treatments before initiating phenotype-specific treatment in step 5. A strong recommendation was also made in favor of using biologic agents and/or aspirin treatment after desensitization in severe asthma when indicated. © Author(s).Item Elderly and aged asthma have different characteristics: results of a multicenter study(Turkiye Klinikleri, 2024) Damadoğlu E.; Öztürk Aktaş Ö.; Gemicioğlu B.; Yilmaz N.; Bozkuş F.; Ayhan V.; Kalpaklioğlu A.F.; Öner Erkekol F.; Havlucu Y.; Erel F.; Aydin Ö.; Ekici A.; Baççioğlu A.; Argun Bariş S.; Köycü Buhari G.; Ceyhan B.; Göksel Ö.; Köse M.; Dursun A.B.; Yildiz F.; Yorgancioğlu A.; Işik S.R.; Ediger D.; Oğuzülgen İ.K.; Demir A.U.; Karakaya G.; Kalyoncu A.F.Background/ aim: Characteristics of asthma in the elderly population is not well-known. The aim of the present study was to evaluate asthma in the elderly population, to compare disease characteristics between patients diagnosed <60 (aged asthma) and ≥60 (elderly asthma) years of age. Materials and methods: The study was a prospective, multicenter, cross-sectional type. A questionnaire was filled out to patients 60 years of age and over, that have been followed for asthma for at least 3 months. Asthma Control Test (ACT), eight-item Morisky Medication Adherence Scale (MMAS-8) was filled out, inhaler device technique was assessed. Results: A total of 399 patients were included from 17 tertiary care centers across the country. Mean age was 67.11 years and 331 (83%) were female. The age at asthma diagnosis was ≥60 in 146 (36.6%) patients. Patients diagnosed ≥60 years were older (p < 0.001), had higher education level (p < 0.001), more commonly had first-degree relative with asthma (p = 0.038), asthma related comorbidities (p = 0.009) and accompanying rhinitis/rhinosinusitis (p = 0.005), had better asthma control (p = 0.001), were using less controller medications (p = 0.014). Inhaler technique was correct in 37% of the patients with no difference in between the groups. Treatment compliance was better in elderly asthma patients (p < 0.001). In the multivariate logistic regression analysis, having well-controlled asthma (odds ratio = 1.61, CI = 1.04–2.51), and high medication adherence rate (odds ratio = 2.43, CI = 1.48–4.0) were associated with being in the elderly asthma group. Conclusion: The characteristics of asthma are different among patients aged 60 years and over which seems to be related to onset age of asthma. In our cohort, the elderly asthma patients had higher education level, and treatment adherence and asthma control was better. Patients diagnosed ≥60 years of age did not have more severe disease. © 2024, Turkiye Klinikleri. All rights reserved.Item Trends in prescribing montelukast in patients with asthma in real-life: Results from the Turkish adult asthma registry(Exon Publications, 2025) Beyaz Ş.; Erdinç M.; Hayme S.; Aslan A.F.; Aydın Ö.; Gökmen D.; Buhari G.K.; Sözener Z.Ç.; Gemicioğlu B.; Bulut İ.; Örçen C.; Özdemir S.K.; Keren M.; Damadoğlu E.; Yakut T.; Kalpaklıoğlu A.F.; Baccıoğlu A.; Yalım S.A.; Yılmaz İ.; Kalkan İ.K.; Uysal M.A.; Niksarlıoğlu E.Y.Ö.; Kalyoncu A.F.; Karakaya G.; Erbay M.; Nayc S.; Tepetam F.M.; Gelincik A.A.; Dirol H.; Göksel Ö.; Karaoğlanoğlu S.; Erkekol F.Ö.; Isık S.R.; Yıldız F.; Yavuz Y.; Karadoğan D.; Bozkurt N.; Şeker Ü.; Oğuzülgen İ.K.; Başyiğit İ.; Barış S.A.; Uçar E.Y.; Erdoğan T.; Polatlı M.; Ediger D.; Günaydın F.E.; Türk M.; Pür L.; Katran Z.Y.; Sekibağ Y.; Aykaç E.F.; Mungan D.; Gül Ö.; Cengiz A.; Akkurt B.; Özden Ş.; Demir S.; Ünal D.; Can A.; Gümüşburun R.; Boğatekin G.; Akten H.S.; İnan S.; Öğüş A.C.; Kavas M.; Yuluğ D.P.; Çakmak M.E.; Kaya S.B.; Alpagat G.; Özgür E.S.; Uzun O.; Gülen Ş.T.; Pekbak G.; Kızılırmak D.; Havlucu Y.; Dönmez H.; Arslan B.; Çetin G.P.; Soyyiğit Ş.; Kara B.Y.; Karakış G.P.; Dursun A.B.; Kendirlinan R.; Öztürk A.B.; Sevinç C.; Şimşek G.Ö.; Abadoğlu Ö.; Çerçi P.; Yücel T.; Yorulmaz İ.; Tezcaner Z.Ç.; Tatar E.Ç.; Süslü A.E.; Özer S.; Dursun E.; Yorgancıoğlu A.; Çelik G.E.Montelukast, a leukotriene receptor antagonist (LTRA) approved for the treatment of asthma and allergic rhinitis, is widely used, though real-world data on its application in asthma management remain limited. This registry-based study evaluated the use of montelukast in adult asthma patients, examining demographic and disease characteristics, asthma control status, asthma phenotypes, presence of atopy, and treatment regimens. Among 2053 patients analyzed, 61.76% (n = 1268; mean age: 46.2 ± 14.3 years), predominantly females (~76%), received montelukast. Montelukast users showed higher rates of allergic rhinitis (P < 0.001), hyper-sensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) (P = 0.008), and chronic rhinosi-nusitis (P = 0.008). Montelukast group also had higher atopy and total IgE levels and tended to be more eosinophilic. Montelukast was commonly preferred in allergic, eosinophilic, NSAID-exacerbated respiratory disease, and severe asthma phenotypes (P < 0.001). Patients receiving Steps 4 and 5 treatments are more likely to be prescribed montelukast (P < 0.001). Montelukast usage was higher among patients with uncontrolled asthma [ACT< 20 (OR:1.29, 95%CI:1.052–1.582, P = 0.014)]. In addition, logistic regression analyses identified the main factors associated with increased montelukast use as; female gender (OR:1.33, 95%CI:1.041–1.713, P = 0.02), presence of atopy (OR:1.46, 95%CI:1.157–1.864, P = 0.002), comorbid allergic rhinitis (OR:2.12, 95%CI:1.679–2.293, P < 0.001), and severe asthma (OR:2.18, 95%CI:1.712–2.784, P < 0.001). These findings reveal that montelukast use is prevalent among asthma patients, particularly in females, middle-aged adults, and those with comorbid allergic rhinitis, uncontrolled asthma, or specific asthma phenotypes, underscoring the factors that influence its prescription in asthma management. © 2025 Codon Publications.